Hepatosplenic T-cell Lymphoma in a Patient with Crohn's Disease

Overview

Journal Nat Rev Gastroenterol Hepatol

Specialty Gastroenterology

Date 2009 Jul 4

PMID 19575026

Citations 11

Authors

Florian Beigel

Matthias Jurgens

Cornelia Tillack

Marion Subklewe

Doris Mayr

Burkhard Goke

Stephan Brand

Thomas Ochsenkuhn

Affiliations

Soon will be listed here.

Abstract

Background: A 58-year-old man who had a 35-year history of Crohn's disease presented to our IBD center with a disease flare, pararectal fistulas and abscess formation. The patient had previously undergone ileocolic resection for a stenosis and his abscesses had been treated by surgical drainage. He had been taking azathioprine therapy for approximately 5.5 years and had received high-dose steroids. He had also previously taken metronidazole and antihypertensive medications.

Investigations: Physical examination, laboratory investigations including hemoglobin levels and white blood cell counts, genetic testing, CT, bone-marrow biopsy, immunophenotyping by fluorescence-activated cell sorting, polymerase chain reaction analyses, fluorescence in situ hybridization, sputum culture and diagnostic splenectomy.

Diagnosis: Hepatosplenic T-cell lymphoma.

Management: Splenectomy, antibiotic therapy and chemotherapy with cyclophosphamide.

Citing Articles

Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.

Shah E, Coburn E, Nayyar A, Lee K, Koliani-Pace J, Siegel C Aliment Pharmacol Ther. 2020; 51(5):527-533.

PMID: 31990422 PMC: 7018581. DOI: 10.1111/apt.15637.

Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.

Yabe M, Medeiros L, Daneshbod Y, Davanlou M, Bueso-Ramos C, Moran E Ann Diagn Pathol. 2017; 26:16-22.

PMID: 28038706 PMC: 5560101. DOI: 10.1016/j.anndiagpath.2016.10.005.

Hepatosplenic T-cell lymphoma in a young immunocompetent man.

Petrova M, Gomes M, Carda J, de Moura J BMJ Case Rep. 2016; 2016.

PMID: 27033291 PMC: 4840752. DOI: 10.1136/bcr-2016-214414.

Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study.

Bewtra M, Newcomb C, Wu Q, Chen L, Xie F, Roy J Ann Intern Med. 2015; 163(4):262-70.

PMID: 26168366 PMC: 4925099. DOI: 10.7326/M14-0960.

Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.

Selvaraj S, Chairez E, Wilson L, Lazarev M, Bass E, Hutfless S Syst Rev. 2013; 2:53.

PMID: 23826928 PMC: 3710465. DOI: 10.1186/2046-4053-2-53.

References

Rosh J, Gross T, Mamula P, Griffiths A, Hyams J . Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?. Inflamm Bowel Dis. 2007; 13(8):1024-30. DOI: 10.1002/ibd.20169. View

Krenacs L, Smyth M, Bagdi E, Krenacs T, Kopper L, Rudiger T . The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity. Blood. 2002; 101(9):3590-3. DOI: 10.1182/blood-2002-09-2908. View

Mittal S, Milner B, Johnston P, Culligan D . A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur J Haematol. 2006; 76(6):531-4. DOI: 10.1111/j.1600-0609.2006.00646.x. View

Van Assche G, Magdelaine-Beuzelin C, DHaens G, Baert F, Noman M, Vermeire S . Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008; 134(7):1861-8. DOI: 10.1053/j.gastro.2008.03.004. View

Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J . Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359(9317):1541-9. DOI: 10.1016/S0140-6736(02)08512-4. View

Jonveaux P, Daniel M, Martel V, Maarek O, Berger R . Isochromosome 7q and trisomy 8 are consistent primary, non-random chromosomal abnormalities associated with hepatosplenic T gamma/delta lymphoma. Leukemia. 1996; 10(9):1453-5. View

Kandiel A, Fraser A, Korelitz B, Brensinger C, Lewis J . Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54(8):1121-5. PMC: 1774897. DOI: 10.1136/gut.2004.049460. View

Aldinucci D, Poletto D, Zagonel V, Rupolo M, Degan M, Nanni P . In vitro and in vivo effects of 2'-deoxycoformycin (Pentostatin) on tumour cells from human gammadelta+ T-cell malignancies. Br J Haematol. 2000; 110(1):188-96. DOI: 10.1046/j.1365-2141.2000.02129.x. View

Ohshima K, Haraoka S, Harada N, Kamimura T, Suzumiya J, Kanda M . Hepatosplenic gammadelta T-cell lymphoma: relation to Epstein-Barr virus and activated cytotoxic molecules. Histopathology. 2000; 36(2):127-35. DOI: 10.1046/j.1365-2559.2000.00804.x. View

10.

Sandborn W, Rutgeerts P, Enns R, Hanauer S, Colombel J, Panaccione R . Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007; 146(12):829-38. DOI: 10.7326/0003-4819-146-12-200706190-00159. View

11.

Belhadj K, Reyes F, Farcet J, Tilly H, Bastard C, Angonin R . Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003; 102(13):4261-9. DOI: 10.1182/blood-2003-05-1675. View

12.

Humphreys M, Cino M, Quirt I, Barth D, Kukreti V . Long-term survival in two patients with hepatosplenic T cell lymphoma treated with interferon-alpha. Leuk Lymphoma. 2008; 49(7):1420-3. DOI: 10.1080/10428190802087488. View

13.

Farcet J, Gaulard P, Marolleau J, Le Couedic J, Henni T, Gourdin M . Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood. 1990; 75(11):2213-9. View

14.

Mudter J, Neurath M . Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut. 2006; 56(2):293-303. PMC: 1856765. DOI: 10.1136/gut.2005.090464. View

15.

Shale M, Kanfer E, Panaccione R, Ghosh S . Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut. 2008; 57(12):1639-41. DOI: 10.1136/gut.2008.163279. View